A B S T R A C T BACKGROUNDMyocardial performance index (MPI)/Tei index measures the LV systolic and LV diastolic function. Several studies have proved its reliability in evaluating the LV systolic and diastolic performance, with clear benefit over other old indices. It is also helpful in determining the prognosis of heart diseases, especially coronary artery disease. Diabetes affects the heart in several ways. The prevalence of coronary artery disease in a patient with diabetes is well known. The cardiac status in prediabetes is not studied extensively. Hence this study was undertaken to assess the myocardial function in prediabetes using MPI. We wanted to assess myocardial performance index (MPI) in prediabetes and correlate myocardial performance index with cardiovascular risk factors like waist hip ratio (WHR), fasting lipid profile (FLP) and body mass index (BMI).
METHODSIn this cross sectional study 200 prediabetics were enrolled as cases and 100 age and sex matched subjects were enrolled as controls. Thorough history, physical examination, biochemical investigations like FBS, PMBS, FLP and Echocardiography for myocardial performance index were done.
RESULTSBody mass index (BMI), waist to hip ratio (WHR), total cholesterol, triglycerides, low density lipoprotein (LDL) and very low-density lipoprotein (VLDL) were significantly higher in prediabetes and high-density lipoprotein (HDL) were significantly lower in prediabetes in comparison to controls (p=0.0001). Out of 200 prediabetic subjects, 23 (11.5%) had abnormal MPI which was statistically significant in comparison with controls (p=0.037) There was no correlation of abnormal myocardial performance index with cardiovascular risk factors like BMI, WHR and fasting lipid profile (FLP).
CONCLUSIONSPrediabetes had abnormal MPI in comparison to controls. However, no correlation was found between cardiovascular risk factors and MPI.
Introduction:Willis–Ekbom disease (WED)/restless legs syndrome (RLS) is a disorder in which the patient has neurologic features such as urge of rhythmic limb movement that may decrease or stop when the limb is moved. In this study, we had tried to compare the severity of WED in different stages of chronic kidney disease (CKD).Materials and Methods:In this study, a total of 300 patients with CKD who were >18 years of age were included. All the participants were subjected to questionnaire for the diagnosis of RLS (essential clinical criteria for the diagnosis of RLS) and a questionnaire on International Restless Legs Syndrome Study Group Rating Scale for its severity.Observation and Results:Our study showed a prevalence of 20% of WED in patients with CKD. Patients with CKD on hemodialysis had significantly more WED than the conservative group (P = 0.0001). Patients with a history of diabetes mellitus showed significant correlation with WED (P = 0.026), while patients who had a history of hypertension showed both diabetes mellitus and hypertension and smoking had no significant relation with WED (P = 0.27, P = 0.23, and P = 0.22, respectively). The different stages of CKD showed significant correlation with WED (P = 0.002), with more WED among patients with stage V CKD. WED was more in patients on hemodialysis (P = 0.0001). The correlation of different stages of CKD with the severity of WED was statistically significant (P = 0.029), with WED being more severe among stage V CKD.Conclusion:WED was more prevalent among patients with CKD who are on maintenance hemodialysis and diabetes mellitus. However, no such relation could be established for hypertension alone. Patients with higher grades of CKD were more prone to have WED symptoms, and the severity of these symptoms increases with the stages of CKD.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.